A new study has demonstrated a promising radioimmunotherapy approach that effectively eliminates cancer stem cells (CSCs) in ovarian cancer models, showing better results than the current standard treatment. The research, published in The Journal of Nuclear Medicine, highlights the use of the radionuclide Terbium-161 (161Tb), which significantly outperformed Lutetium-177 (177Lu) in killing ovarian CSCs both in vitro and in vivo. This advancement could pave the way for more targeted and personalized cancer treatments, offering hope for improved patient outcomes. The results indicate a vital step towards clinical implementation of 161Tb-based therapies, potentially enhancing diagnosis and monitoring in cancer care.
Fri, 01 Aug 2025 16:19:00 GMT | News-Medical